Oncology intelligence · live daily

The oncology update.
Already interpreted.

OncRef watches every approval, readout, pipeline move and congress abstract — and delivers what it means for your asset, pre-cut for Medical Affairs, Clinical Development and Commercial. Updated daily.

6,200+ oncologists read us16,000+ congress abstracts scored17,000+ companies tracked
OncRef falcon diving
Signal · NSCLC
FDA approves Hyrnuo for HER2 TKD NSCLC
CompetitiveMedical
FDAHyrnuo approved · HER2 TKD-mutant NSCLCREADOUTEVOKE-03 misses primary endpointCONGRESSWCLC solidifies precision first-line strategiesPIPELINEBispecifics & engineered CTLA-4 advance post-IOREGULATORYNew Fast Track designations in thoracic oncologyFDAHyrnuo approved · HER2 TKD-mutant NSCLCREADOUTEVOKE-03 misses primary endpointCONGRESSWCLC solidifies precision first-line strategiesPIPELINEBispecifics & engineered CTLA-4 advance post-IOREGULATORYNew Fast Track designations in thoracic oncology
The scale

OncRef logs over 1,500 oncology data updates every day.

Trial changes, publications, approvals, press releases and congress abstracts — more than 400,000 in the past year. OncRef scans them and pulls the relevant insights for you.

The OncRef falcon flies in and shines a light on the trials, drugs, publications and guidelines that matter to your asset
Every day, OncRef scans the oncology landscape.
It spots what changed…
…and lights up what matters to your asset.
The problem

Oncology moves faster than any team can read.

44K+
oncology publications / yr
15K+
active oncology trials
50+
FDA oncology approvals / yr
From signal to strategy

Pre-computed, not prompted.

Oncology updates go in. Answers for each of your teams come out — already interpreted, no prompting required.

Trial results
Congress updates
Publications
Competitor moves
The OncRef falcon turning signals into strategy
Interpreted by OncRef
Medical AffairsEvidence & scientific exchange
Clinical DevelopmentTrials, endpoints & landscape
Competitive PositioningPipeline, assets & strategy
Commercial ImpactLabel, population & market shifts
01 / Congress coverage

Thousands of abstracts in. Four answers out.

Every abstract at ASCO, ESMO, ASH and beyond is read, scored and routed to competitive positioning, medical strategy, clinical development and commercial impact.

Thousands of abstracts in. Four answers out.
Evidence gaps

See where the landscape is crowded — and where the opportunity remains.

Evidence gap analysisIllustrative example
Study AStudy BStudy CStudy D
Population
Biomarker
Line of therapy
Endpoint
Efficacy
Safety
Comparator
Covered by evidence Partly covered Evidence gap
Congress coverage

Coverage that doesn't stop at the abstract.

Exactly what you get from every congress we cover:

AbstractsKey data and takeaways
PostersVisual data summaries
PresentationsFull analysis and context
Competitive implicationsWhat it means for your asset
Built to be trusted, not just fast

Ingested daily. Normalized deterministically. Traced back to the source.

OncRef / Strategy IntelligenceExample workspace · Oncology
Portfolio intelligence
Your oncology landscape, in focus.
Trials
Competitive activity
Signals
What changed
Impact
Why it matters
Congress
New data in a shared biomarker population
Implications for differentiation, evidence needs and field questions
What this means to you: First read on your differentiation story — the same day, not a week later.
↳ Traced to: Peer-reviewed publications
Clinical trial
Competitor development program expands
New trial footprint mapped against your asset's target indications
What this means to you: Competitive footprint vs. your asset, refreshed the day it moved.
↳ Traced to: Clinical trial registries
Guidelines
Treatment pathway update identified
Relevance flagged for scientific exchange and evidence planning
What this means to you: Your evidence plan stays ahead of the pathway, not behind it.
↳ Traced to: Treatment guidelines
Label
Prescribing information revised
Population and line-of-therapy changes vs. your label
What this means to you: Label-to-label comparison, ready for medical review.
↳ Traced to: Prescribing information
Gold signals — the interpreted update, pre-cut for pharma workflows.
Sources ingested daily
Clinical trial registriesCompany pipelinesTreatment guidelinesIndications & MOAsPrescribing informationPress releasesPeer-reviewed publicationsEpidemiology statistics

Every drug, company, trial and guideline is mapped to a single normalized entity — so a claim in your brief is always one click from its origin. Built for MLR-minded teams.

Why teams switch

Less to read. More to decide.

Traditional intelligence services hand you the haystack. OncRef hands you the needle — and tells you why it matters.

Falcon over a medical data network
Raw abstract & news feeds to triage
Interpreted update, pre-cut by team
You write the prompt, then check it
Pre-computed — no prompting
One view for every function
Medical, Clin Dev, Commercial, Competitive lenses
Weekly analyst turnaround
Updated daily
Hard to trace a claim to its origin
Every line traced back to source
Who it's for

One evidence layer. Every team with a pipeline.

Pharma & biotech

Medical Affairs · Clinical Development · Commercial · BD

Annual subscriptions by team and indication

Investors & VC

Pipeline and landscape research across companies, mechanisms and indications

Research-seat access

Oncologists

The interpreted update at the point of care — trials, labels and guidelines for the patients in front of you

Free for verified clinicians
“I love this because I can go in and pick my cancer type. Not every app is oncology specific. Especially for oncology centric providers, being able to start at a very specific indication offers more value than other products on the market.”
Monika Buczek, PhDMonika Buczek, PhDDirector, Taconic Biosciences Strategy, Operations, Product, and Innovation
“This is really cool. I've never seen anything like this.”
Patrick Tucker, PhDPatrick Tucker, PhDVP of Medical Communications
Supported byGoogleNVIDIAAWS
Build your briefing · takes 60 seconds

Tell us what you can't afford to miss.

Choose your team, indications and deliverables — newsletter, custom dashboard or congress coverage. We'll send a sample brief built on your scope. No obligation — or request a demo and we'll set up a call.

Which team are you briefing?

We pre-cut every update for the lens your team works in.

Your brief: your team · pick indications

No obligation. Your selections stay confidential and are used only to prepare your brief.

OncRef falcon surveying a congress hall

Change the pace of cancer research — so every patient gets the care they deserve.